| Year |
Citation |
Score |
| 2023 |
Byers HA, Brooks AN, Vangala JR, Grible JM, Feygin A, Clevenger CV, Harrell JC, Radhakrishnan SK. Evaluation of the NRF1-proteasome axis as a therapeutic target in breast cancer. Scientific Reports. 13: 15843. PMID 37739987 DOI: 10.1038/s41598-023-43121-x |
0.413 |
|
| 2023 |
Hathaway CA, Rice MS, Collins LC, Chen D, Frank DA, Walker S, Clevenger CV, Tamimi RM, Tworoger SS, Hankinson SE. Prolactin levels and breast cancer risk by tumor expression of prolactin-related markers. Breast Cancer Research : Bcr. 25: 24. PMID 36882838 DOI: 10.1186/s13058-023-01618-3 |
0.405 |
|
| 2022 |
Clevenger CV, Rui H. Breast cancer and prolactin - new mechanisms and models. Endocrinology. PMID 35922139 DOI: 10.1210/endocr/bqac122 |
0.456 |
|
| 2021 |
Woock AE, Grible JM, Olex AL, Harrell JC, Zot P, Idowu M, Clevenger CV. Serine residues 726 and 780 have nonredundant roles regulating STAT5a activity in luminal breast cancer. Scientific Reports. 11: 13506. PMID 34188118 DOI: 10.1038/s41598-021-92830-8 |
0.463 |
|
| 2021 |
Grible JM, Zot P, Olex AL, Hedrick SE, Harrell JC, Woock AE, Idowu MO, Clevenger CV. The human intermediate prolactin receptor is a mammary proto-oncogene. Npj Breast Cancer. 7: 37. PMID 33772010 DOI: 10.1038/s41523-021-00243-7 |
0.463 |
|
| 2021 |
Craig JM, Turner TH, Harrell JC, Clevenger CV. Prolactin Drives a Dynamic STAT5A/HDAC6/HMGN2 Cis-Regulatory Landscape Exploitable in ER+ Breast Cancer. Endocrinology. PMID 33589921 DOI: 10.1210/endocr/bqab036 |
0.355 |
|
| 2020 |
Hakim S, Craig JM, Koblinski JE, Clevenger CV. Inhibition of the Activity of Cyclophilin A Impedes Prolactin Receptor-Mediated Signaling, Mammary Tumorigenesis, and Metastases. Iscience. 23: 101581. PMID 33083747 DOI: 10.1016/J.Isci.2020.101581 |
0.547 |
|
| 2020 |
Woock AE, Grible JM, Zot P, Harrell JC, Michael I, Clevenger CV. SAT-139 STAT5A Regulation by Serine Phosphorylation in Breast Cancer Journal of the Endocrine Society. 4. DOI: 10.1210/Jendso/Bvaa046.1035 |
0.584 |
|
| 2020 |
Grible JM, Zot P, Harrell JC, Idowu M, Clevenger CV. SAT-130 The Intermediate Prolactin Receptor Is a Breast Cancer Oncogene Journal of the Endocrine Society. 4. DOI: 10.1210/Jendso/Bvaa046.1033 |
0.546 |
|
| 2020 |
Adashek JJ, Szeto C, Sanborn JZ, Reddy SK, Toor AA, Danielides S, Smith S, Grossman SR, Clevenger CV, Faber A, Ferreira-Gonzalez A, Boikos SA. Targetable immune checkpoint molecules may be significantly differentially expressed in minority ethnicities. Journal of Clinical Oncology. 38: 3576-3576. DOI: 10.1200/Jco.2020.38.15_Suppl.3576 |
0.338 |
|
| 2020 |
Grible JM, Hedrick SE, Clevenger CV. Abstract P4-08-02: The human intermediate prolactin receptor is a breast cancer oncogene Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P4-08-02 |
0.562 |
|
| 2019 |
Grible JM, Clevenger CV. Abstract 870: The role of the intermediate prolactin receptor in breast cancer oncogenesis Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-870 |
0.489 |
|
| 2019 |
Hakim S, Hedrick SE, Craig JM, Clevenger CV. Abstract 4508: Cyclophilin A as a molecular switch regulating PRLr-Jak2 complex-mediated signaling, mammary tumorigenesis, and metastasis Cancer Research. 79: 4508-4508. DOI: 10.1158/1538-7445.Am2019-4508 |
0.561 |
|
| 2018 |
Volker SE, Hedrick SE, Feeney YB, Clevenger CV. Cyclophilin A Function in Mammary Epithelium Impacts Jak2/Stat5 Signaling, Morphogenesis, Differentiation, and Tumorigenesis in the Mammary Gland. Cancer Research. PMID 29959151 DOI: 10.1158/0008-5472.Can-17-2892 |
0.49 |
|
| 2018 |
Mapes J, Anandan L, Li Q, Neff A, Clevenger CV, Bagchi IC, Bagchi MK. Aberrantly high expression of the CUB and zona pellucida-like domain-containing protein 1 (CUZD1) in mammary epithelium leads to breast tumorigenesis. The Journal of Biological Chemistry. PMID 29321207 DOI: 10.1074/Jbc.Ra117.000162 |
0.535 |
|
| 2018 |
Craig JM, Schauwecker SM, Clevenger CV. Abstract B11: HDAC6 as a therapeutic target in human breast cancer Molecular Cancer Research. 16. DOI: 10.1158/1557-3125.Advbc17-B11 |
0.519 |
|
| 2017 |
Costa R, Santa-Maria CA, Scholtens DM, Jain S, Flaum L, Gradishar WJ, Clevenger CV, Kaklamani VG. A pilot study of cabergoline for the treatment of metastatic breast cancer. Breast Cancer Research and Treatment. PMID 28674764 DOI: 10.1007/S10549-017-4370-X |
0.495 |
|
| 2017 |
Costa RLB, Santa-Maria CA, Scholtens DM, Jain S, Gradishar WJ, Clevenger CV, Kaklamani VG. A pilot phase II trial of cabergoline in the treatment of metastatic breast cancer. Journal of Clinical Oncology. 35: e12568-e12568. DOI: 10.1200/Jco.2017.35.15_Suppl.E12568 |
0.443 |
|
| 2017 |
Clevenger C, Craig J, Fiorillo A, Feeney Y, Harrell J, Medler T. Abstract P3-06-08: HDAC6 deacetylates HMGN2 to regulate Stat5a activity and breast cancer growth Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P3-06-08 |
0.473 |
|
| 2016 |
Schauwecker SM, Kim JJ, Licht JD, Clevenger CV. Histone H1 and Chromosomal Protein HMGN2 Regulate Prolactin-Induced STAT5 Transcription Factor Recruitment and Function in Breast Cancer Cells. The Journal of Biological Chemistry. PMID 28035005 DOI: 10.1074/Jbc.M116.764233 |
0.47 |
|
| 2016 |
Puchalapalli M, Zeng X, Mu L, Anderson A, Hix Glickman L, Zhang M, Sayyad MR, Mosticone Wangensteen S, Clevenger CV, Koblinski JE. NSG Mice Provide a Better Spontaneous Model of Breast Cancer Metastasis than Athymic (Nude) Mice. Plos One. 11: e0163521. PMID 27662655 DOI: 10.1371/Journal.Pone.0163521 |
0.435 |
|
| 2016 |
Harrington KM, Clevenger CV. Identification of NEK3 Threonine 165 as a Novel Regulatory Phosphorylation Site that Modulates Focal Adhesion Remodeling Necessary for Breast Cancer Cell Migration. The Journal of Biological Chemistry. PMID 27489110 DOI: 10.1074/Jbc.M116.726190 |
0.549 |
|
| 2016 |
Medler TR, Craig JM, Fiorillo AA, Feeney YB, Harrell JC, Clevenger CV. HDAC6 Deacetylates HMGN2 to Regulate Stat5a Activity and Breast Cancer Growth. Molecular Cancer Research : McR. PMID 27358110 DOI: 10.1158/1541-7786.MCR-16-0109 |
0.432 |
|
| 2015 |
Rizk SS, Kouadio JL, Szymborska A, Duguid EM, Mukherjee S, Zheng J, Clevenger CV, Kossiakoff AA. Engineering synthetic antibody binders for allosteric inhibition of prolactin receptor signaling. Cell Communication and Signaling : Ccs. 13: 1. PMID 25589173 DOI: 10.1186/S12964-014-0080-8 |
0.353 |
|
| 2015 |
Rice MS, Tworoger SS, Bertrand KA, Hankinson SE, Rosner BA, Feeney YB, Clevenger CV, Tamimi RM. Immunoassay and Nb2 lymphoma bioassay prolactin levels and mammographic density in premenopausal and postmenopausal women the Nurses' Health Studies. Breast Cancer Research and Treatment. 149: 245-53. PMID 25503962 DOI: 10.1007/S10549-014-3232-Z |
0.317 |
|
| 2015 |
Tworoger SS, Rice MS, Rosner BA, Feeney YB, Clevenger CV, Hankinson SE. Bioactive prolactin levels and risk of breast cancer: a nested case-control study. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 24: 73-80. PMID 25315962 DOI: 10.1158/1055-9965.Epi-14-0896 |
0.441 |
|
| 2015 |
Harrington KM, Clevenger CV. Abstract 529: Phosphorylation of Thr165 within the activation loop of Nek3 kinase is necessary for its pro-migratory function in breast cancer cells Cancer Research. 75: 529-529. DOI: 10.1158/1538-7445.Am2015-529 |
0.571 |
|
| 2014 |
Rahman T, Clevenger CV, Kaklamani V, Lauriello J, Campbell A, Malwitz K, Kirkland RS. Antipsychotic treatment in breast cancer patients. The American Journal of Psychiatry. 171: 616-21. PMID 24880509 DOI: 10.1176/Appi.Ajp.2013.13050650 |
0.484 |
|
| 2013 |
Wang J, Gupta A, Hu H, Chatterton RT, Clevenger CV, Khan SA. Comment on "Progesterone/RANKL is a major regulatory axis in the human breast". Science Translational Medicine. 5: 215le4. PMID 24337478 DOI: 10.1126/Scitranslmed.3006883 |
0.442 |
|
| 2013 |
Fought AJ, McGathey C, Scholtens DM, Heinz RE, Lowe R, Feeney YB, Lee O, Kmiecik TE, Wolfman JA, Clevenger CV, Gann PH, Gapstur S, Chatterton RT, Khan SA. Hormonal determinants of nipple aspirate fluid yield among breast cancer cases and screening controls. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 22: 2277-84. PMID 24049126 DOI: 10.1158/1055-9965.Epi-12-0434 |
0.404 |
|
| 2013 |
Fiorillo AA, Medler TR, Feeney YB, Wetz SM, Tommerdahl KL, Clevenger CV. The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer. The American Journal of Pathology. 182: 217-33. PMID 23159947 DOI: 10.1016/J.Ajpath.2012.09.021 |
0.558 |
|
| 2013 |
Wu AM, Dalvi P, Lu X, Yang M, Riddick DS, Matthews J, Clevenger CV, Ross DD, Harper PA, Ito S. Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells. Molecular Pharmacology. 83: 377-88. PMID 23150485 DOI: 10.1124/Mol.112.082362 |
0.515 |
|
| 2012 |
Zhao H, Pearson EK, Brooks DC, Coon JS, Chen D, Demura M, Zhang M, Clevenger CV, Xu X, Veenstra TD, Chatterton RT, DeMayo FJ, Bulun SE. A humanized pattern of aromatase expression is associated with mammary hyperplasia in mice. Endocrinology. 153: 2701-13. PMID 22508516 DOI: 10.1210/En.2011-1761 |
0.464 |
|
| 2012 |
Harrington K, Clevenger C. Abstract 472: Nek3 kinase in breast cancer pathogenesis: The role of paxillin phosphorylation Cancer Research. 72: 472-472. DOI: 10.1158/1538-7445.Am2012-472 |
0.548 |
|
| 2012 |
Zeng X, Zheng J, Feeney Y, Harrington K, Clevenger C. Abstract 3836: Enhancement of doxorubicin cytotoxicity in breast cancer by NIM811, A non-immunosuppressive cyclosporine A analog Cancer Research. 72: 3836-3836. DOI: 10.1158/1538-7445.Am2012-3836 |
0.539 |
|
| 2012 |
Ratajczak C, Clevenger C. Abstract 3077: Nek3/Vav2 modulation of the expression of genes involved in breast cancer pathogenesis Cancer Research. 72: 3077-3077. DOI: 10.1158/1538-7445.Am2012-3077 |
0.569 |
|
| 2011 |
Zheng J, Fang F, Zeng X, Medler TR, Fiorillo AA, Clevenger CV. Negative cross talk between NFAT1 and Stat5 signaling in breast cancer. Molecular Endocrinology (Baltimore, Md.). 25: 2054-64. PMID 21964595 DOI: 10.1210/Me.2011-1141 |
0.546 |
|
| 2011 |
Fiorillo AA, Medler TR, Feeney YB, Liu Y, Tommerdahl KL, Clevenger CV. HMGN2 inducibly binds a novel transactivation domain in nuclear PRLr to coordinate Stat5a-mediated transcription. Molecular Endocrinology (Baltimore, Md.). 25: 1550-64. PMID 21816901 DOI: 10.1210/Me.2011-0106 |
0.404 |
|
| 2010 |
Galbaugh T, Feeney YB, Clevenger CV. Prolactin receptor-integrin cross-talk mediated by SIRPα in breast cancer cells. Molecular Cancer Research : McR. 8: 1413-24. PMID 20826546 DOI: 10.1158/1541-7786.Mcr-10-0130 |
0.583 |
|
| 2010 |
Fang F, Zheng J, Galbaugh TL, Fiorillo AA, Hjort EE, Zeng X, Clevenger CV. Cyclophilin B as a co-regulator of prolactin-induced gene expression and function in breast cancer cells. Journal of Molecular Endocrinology. 44: 319-29. PMID 20237142 DOI: 10.1677/Jme-09-0140 |
0.547 |
|
| 2010 |
Clevenger C, Zheng J, Harrington K, Zeng X. Abstract P2-19-04: Anti-Jak2 and Breast Cancer Activity of NIM811, a Non-Immunosuppressive Cyclosporine A Analog Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P2-19-04 |
0.562 |
|
| 2009 |
Clevenger CV, Gadd SL, Zheng J. New mechanisms for PRLr action in breast cancer. Trends in Endocrinology and Metabolism: Tem. 20: 223-9. PMID 19535262 DOI: 10.1016/J.Tem.2009.03.001 |
0.523 |
|
| 2009 |
Bauer K, Kretzschmar AK, Cvijic H, Blumert C, Löffler D, Brocke-Heidrich K, Schiene-Fischer C, Fischer G, Sinz A, Clevenger CV, Horn F. Cyclophilins contribute to Stat3 signaling and survival of multiple myeloma cells. Oncogene. 28: 2784-95. PMID 19503092 DOI: 10.1038/Onc.2009.142 |
0.351 |
|
| 2009 |
Fang F, Flegler AJ, Du P, Lin S, Clevenger CV. Expression of cyclophilin B is associated with malignant progression and regulation of genes implicated in the pathogenesis of breast cancer. The American Journal of Pathology. 174: 297-308. PMID 19056847 DOI: 10.2353/Ajpath.2009.080753 |
0.559 |
|
| 2009 |
Fang F, Rycyzyn MA, Clevenger CV. Role of c-Myb during prolactin-induced signal transducer and activator of transcription 5a signaling in breast cancer cells. Endocrinology. 150: 1597-606. PMID 19036881 DOI: 10.1210/En.2008-1079 |
0.504 |
|
| 2008 |
Zheng J, Koblinski JE, Dutson LV, Feeney YB, Clevenger CV. Prolyl isomerase cyclophilin A regulation of Janus-activated kinase 2 and the progression of human breast cancer. Cancer Research. 68: 7769-78. PMID 18829531 DOI: 10.1158/0008-5472.Can-08-0639 |
0.561 |
|
| 2008 |
Lin SY, Yang J, Everett AD, Clevenger CV, Koneru M, Mishra PJ, Kamen B, Banerjee D, Glod J. The isolation of novel mesenchymal stromal cell chemotactic factors from the conditioned medium of tumor cells. Experimental Cell Research. 314: 3107-17. PMID 18722367 DOI: 10.1016/J.Yexcr.2008.07.028 |
0.38 |
|
| 2008 |
Fang F, Antico G, Zheng J, Clevenger CV. Quantification of PRL/Stat5 signaling with a novel pGL4-CISH reporter. Bmc Biotechnology. 8: 11. PMID 18254957 DOI: 10.1186/1472-6750-8-11 |
0.474 |
|
| 2008 |
Swaminathan G, Varghese B, Thangavel C, Carbone CJ, Plotnikov A, Kumar KG, Jablonski EM, Clevenger CV, Goffin V, Deng L, Frank SJ, Fuchs SY. Prolactin stimulates ubiquitination, initial internalization, and degradation of its receptor via catalytic activation of Janus kinase 2. The Journal of Endocrinology. 196: R1-7. PMID 18252943 DOI: 10.1677/Joe-07-0554 |
0.445 |
|
| 2008 |
Clevenger CV, Zheng J, Jablonski EM, Galbaugh TL, Fang F. From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics. Journal of Mammary Gland Biology and Neoplasia. 13: 147-56. PMID 18246318 DOI: 10.1007/S10911-008-9074-8 |
0.497 |
|
| 2008 |
McHale K, Tomaszewski JE, Puthiyaveettil R, Livolsi VA, Clevenger CV. Altered expression of prolactin receptor-associated signaling proteins in human breast carcinoma. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 21: 565-71. PMID 18246042 DOI: 10.1038/Modpathol.2008.7 |
0.522 |
|
| 2007 |
Miller SL, Antico G, Raghunath PN, Tomaszewski JE, Clevenger CV. Nek3 kinase regulates prolactin-mediated cytoskeletal reorganization and motility of breast cancer cells. Oncogene. 26: 4668-78. PMID 17297458 DOI: 10.1038/Sj.Onc.1210264 |
0.716 |
|
| 2007 |
Keeler C, Jablonski EM, Albert YB, Taylor BD, Myszka DG, Clevenger CV, Hodsdon ME. The kinetics of binding human prolactin, but not growth hormone, to the prolactin receptor vary over a physiologic pH range. Biochemistry. 46: 2398-410. PMID 17279774 DOI: 10.1021/Bi061958V |
0.345 |
|
| 2006 |
Gadd SL, Clevenger CV. Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications. Molecular Endocrinology (Baltimore, Md.). 20: 2734-46. PMID 16840534 DOI: 10.1210/Me.2006-0114 |
0.492 |
|
| 2006 |
Li Y, Clevenger CV, Minkovsky N, Kumar K, Raghunath PN, Tomaszewski JE, Spiegelman VS, Fuchs SY. Stabilization of prolactin receptor in breast cancer cells Oncogene. 25: 1896-1902. PMID 16278670 DOI: 10.1038/Sj.Onc.1209214 |
0.55 |
|
| 2005 |
Miller SL, DeMaria JE, Freier DO, Riegel AM, Clevenger CV. Novel association of Vav2 and Nek3 modulates signaling through the human prolactin receptor. Molecular Endocrinology (Baltimore, Md.). 19: 939-49. PMID 15618286 DOI: 10.1210/Me.2004-0443 |
0.695 |
|
| 2004 |
Clevenger CV. Roles and regulation of stat family transcription factors in human breast cancer. The American Journal of Pathology. 165: 1449-60. PMID 15509516 DOI: 10.1016/S0002-9440(10)63403-7 |
0.524 |
|
| 2003 |
Clevenger CV. Role of prolactin/prolactin receptor signaling in human breast cancer. Breast Disease. 18: 75-86. PMID 15687690 DOI: 10.3233/Bd-2003-18108 |
0.576 |
|
| 2003 |
Clevenger CV. Nuclear localization and function of polypeptide ligands and their receptors: a new paradigm for hormone specificity within the mammary gland? Breast Cancer Research : Bcr. 5: 181-7. PMID 12817988 DOI: 10.1186/Bcr601 |
0.411 |
|
| 2003 |
Syed F, Rycyzyn MA, Westgate L, Clevenger CV. A novel and functional interaction between cyclophilin A and prolactin receptor. Endocrine. 20: 83-90. PMID 12668872 DOI: 10.1385/Endo:20:1-2:83 |
0.481 |
|
| 2003 |
Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocrine Reviews. 24: 1-27. PMID 12588805 DOI: 10.1210/Er.2001-0036 |
0.55 |
|
| 2002 |
Kline JB, Rycyzyn MA, Clevenger CV. Characterization of a novel and functional human prolactin receptor isoform (deltaS1PRLr) containing only one extracellular fibronectin-like domain. Molecular Endocrinology (Baltimore, Md.). 16: 2310-22. PMID 12351696 DOI: 10.1210/Me.2001-0033 |
0.446 |
|
| 2002 |
Rycyzyn MA, Clevenger CV. The intranuclear prolactin/cyclophilin B complex as a transcriptional inducer. Proceedings of the National Academy of Sciences of the United States of America. 99: 6790-5. PMID 11997457 DOI: 10.1073/Pnas.092160699 |
0.385 |
|
| 2002 |
Clevenger CV, Kline JB. Prolactin receptor signal transduction. Lupus. 10: 706-18. PMID 11721697 DOI: 10.1191/096120301717164949 |
0.318 |
|
| 2001 |
Clevenger CV. An old epithelial cell never dies, it just agonesces away. Trends in Endocrinology and Metabolism: Tem. 12: 183-4. PMID 11397636 DOI: 10.1016/S1043-2760(01)00416-7 |
0.429 |
|
| 2001 |
Kline JB, Clevenger CV. Identification and characterization of the prolactin-binding protein in human serum and milk. The Journal of Biological Chemistry. 276: 24760-6. PMID 11337493 DOI: 10.1074/Jbc.M011786200 |
0.391 |
|
| 2001 |
Kline JB, Moore DJ, Clevenger CV. Activation and association of the Tec tyrosine kinase with the human prolactin receptor: mapping of a Tec/Vav1-receptor binding site. Molecular Endocrinology (Baltimore, Md.). 15: 832-41. PMID 11328862 DOI: 10.1210/Mend.15.5.0631 |
0.46 |
|
| 2001 |
Rycyzyn MA, Clevenger CV. Role of cyclophilins in somatolactogenic action. Annals of the New York Academy of Sciences. 917: 514-21. PMID 11268379 DOI: 10.1111/J.1749-6632.2000.Tb05416.X |
0.394 |
|
| 2000 |
Clevenger CV, Rycyzyn MA. Translocation and action of polypeptide hormones within the nucleus. Relevance to lactogenic transduction. Advances in Experimental Medicine and Biology. 480: 77-84. PMID 10959412 DOI: 10.1007/0-306-46832-8_9 |
0.367 |
|
| 2000 |
Rycyzyn MA, Reilly SC, O'Malley K, Clevenger CV. Role of cyclophilin B in prolactin signal transduction and nuclear retrotranslocation. Molecular Endocrinology (Baltimore, Md.). 14: 1175-86. PMID 10935542 DOI: 10.1210/Mend.14.8.0508 |
0.414 |
|
| 2000 |
Kline JB, Roehrs H, Clevenger CV. Functional characterization of the intermediate isoform of the human prolactin receptor. The Journal of Biological Chemistry. 274: 35461-8. PMID 10585417 DOI: 10.1074/Jbc.274.50.35461 |
0.464 |
|
| 1999 |
Maus MV, Reilly SC, Clevenger CV. Prolactin as a chemoattractant for human breast carcinoma. Endocrinology. 140: 5447-50. PMID 10537179 DOI: 10.1210/Endo.140.11.7245 |
0.57 |
|
| 1998 |
Clevenger CV, Freier DO, Kline JB. Prolactin receptor signal transduction in cells of the immune system. The Journal of Endocrinology. 157: 187-97. PMID 9659281 DOI: 10.1677/Joe.0.1570187 |
0.333 |
|
| 1998 |
Chang WP, Ye Y, Clevenger CV. Stoichiometric structure-function analysis of the prolactin receptor signaling domain by receptor chimeras Molecular and Cellular Biology. 18: 896-905. PMID 9447986 DOI: 10.1128/Mcb.18.2.896 |
0.36 |
|
| 1997 |
Clevenger CV, Plank TL. Prolactin as an autocrine/paracrine factor in breast tissue Journal of Mammary Gland Biology and Neoplasia. 2: 59-68. PMID 10887520 DOI: 10.1023/A:1026325630359 |
0.507 |
|
| 1997 |
Reynolds C, Montone KT, Powell CM, Tomaszewski JE, Clevenger CV. Expression of prolactin and its receptor in human breast carcinoma. Endocrinology. 138: 5555-60. PMID 9389544 DOI: 10.1210/Endo.138.12.5605 |
0.5 |
|
| 1997 |
Clevenger CV, Thickman K, Ngo W, Chang WP, Takayama S, Reed JC. Role of Bag-1 in the survival and proliferation of the cytokine-dependent lymphocyte lines, Ba/F3 and Nb2. Molecular Endocrinology (Baltimore, Md.). 11: 608-18. PMID 9139804 DOI: 10.1210/Mend.11.5.9925 |
0.371 |
|
| 1996 |
Chang WP, Clevenger CV. Modulation of growth factor receptor function by isoform heterodimerization. Proceedings of the National Academy of Sciences of the United States of America. 93: 5947-52. PMID 8650199 DOI: 10.1073/Pnas.93.12.5947 |
0.429 |
|
| 1996 |
Luger S, Ratajczak J, Ratajczak M, Kuczynski W, DiPaola R, Ngo W, Clevenger C, Gewirtz A. A functional analysis of protooncogene Vav's role in adult human hematopoiesis Blood. 87: 1326-1334. DOI: 10.1182/Blood.V87.4.1326.Bloodjournal8741326 |
0.358 |
|
| 1995 |
Prystowsky MB, Clevenger CV. Prolactin as a second messenger for interleukin 2. Immunomethods. 5: 49-55. PMID 7842249 DOI: 10.1006/Immu.1994.1037 |
0.402 |
|
| 1995 |
Clevenger CV, Ngo W, Sokol DL, Luger SM, Gewirtz AM. Vav is necessary for prolactin-stimulated proliferation and is translocated into the nucleus of a T-cell line. The Journal of Biological Chemistry. 270: 13246-53. PMID 7768923 DOI: 10.1074/Jbc.270.22.13246 |
0.454 |
|
| 1994 |
Prystowsky JH, Clevenger CV, Zheng ZS. Epidermal growth factor induces ornithine decarboxylase in SV40-immortalized human keratinocytes. Experimental Dermatology. 2: 125-32. PMID 8162329 DOI: 10.1111/J.1600-0625.1993.Tb00020.X |
0.342 |
|
| 1994 |
Clevenger CV, Medaglia MV. The protein tyrosine kinase P59fyn is associated with prolactin (PRL) receptor and is activated by PRL stimulation of T-lymphocytes. Molecular Endocrinology (Baltimore, Md.). 8: 674-81. PMID 7935483 DOI: 10.1210/Mend.8.6.7935483 |
0.426 |
|
| 1993 |
Aird F, Clevenger CV, Prystowsky MB, Redei E. Corticotropin-releasing factor mRNA in rat thymus and spleen. Proceedings of the National Academy of Sciences of the United States of America. 90: 7104-8. PMID 8346222 DOI: 10.1073/Pnas.90.15.7104 |
0.309 |
|
| 1993 |
Prystowsky JH, Clevenger CV, Zheng ZS. Inhibition of ornithine decarboxylase activity and cell proliferation by ultraviolet B radiation in EGF-stimulated cultured human epidermal keratinocytes. The Journal of Investigative Dermatology. 101: 54-8. PMID 8331297 DOI: 10.1111/1523-1747.Ep12359508 |
0.348 |
|
| 1992 |
Clevenger CV, Sillman AL, Hanley-Hyde J, Prystowsky MB. Requirement for prolactin during cell cycle regulated gene expression in cloned T-lymphocytes. Endocrinology. 130: 3216-22. PMID 1534539 DOI: 10.1210/Endo.130.6.1534539 |
0.39 |
|
| 1991 |
Clevenger CV, Sillman AL, Prystowsky MB. Interleukin-2 driven nuclear translocation of prolactin in cloned T-lymphocytes. Endocrinology. 127: 3151-9. PMID 2147410 DOI: 10.1210/Endo-127-6-3151 |
0.321 |
|
| 1991 |
Clevenger CV, Altmann SW, Prystowsky MB. Requirement of nuclear prolactin for interleukin-2--stimulated proliferation of T lymphocytes. Science (New York, N.Y.). 253: 77-9. PMID 2063207 DOI: 10.1126/Science.2063207 |
0.376 |
|
| 1990 |
Clevenger CV, Russell DH, Appasamy PM, Prystowsky MB. Regulation of interleukin 2-driven T-lymphocyte proliferation by prolactin. Proceedings of the National Academy of Sciences of the United States of America. 87: 6460-4. PMID 2143585 DOI: 10.1073/Pnas.87.16.6460 |
0.408 |
|
| 1987 |
Clevenger CV, Epstein AL, Bauer KD. Modulation of the nuclear antigen p105 as a function of cell-cycle progression. Journal of Cellular Physiology. 130: 336-43. PMID 3549742 DOI: 10.1002/Jcp.1041300305 |
0.319 |
|
| 1987 |
Clevenger CV, Epstein AL, Bauer KD. Quantitative analysis of a nuclear antigen in interphase and mitotic cells. Cytometry. 8: 280-6. PMID 3297564 DOI: 10.1002/Cyto.990080308 |
0.3 |
|
| Show low-probability matches. |